Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/ijgc-2019-000441 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics.
Eur J Cancer
January 2025
Department of Medical Oncology, Institut régional du Cancer de Montpellier (ICM), Montpellier, France; Société Française de Médecine Prédictive et Personnalisée (SFMPP), Montpellier, France; Center for Ecological and Evolutionary Cancer Research (CREEC), Montpellier University, Montpellier, France. Electronic address:
Background: Poly (ADP ribose) polymerase inhibitors (PARPis) are a treatment option for patients with advanced high-grade serous or endometrioid ovarian carcinoma (OC). Recent guidelines have clarified how homologous recombination deficiency (HRD) may influence treatment decision-making in this setting. As a result, numerous companion diagnostic assays (CDx) have been developed to identify HRD.
View Article and Find Full Text PDFDevelopment of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation.
Cancers (Basel)
June 2023
Institut für Hämatopathologie Hamburg, 22547 Hamburg, Germany.
The worldwide approval of the combination maintenance therapy of olaparib and bevacizumab in advanced high-grade serous ovarian cancer requires complex molecular diagnostic assays that are sufficiently robust for the routine detection of driver mutations in homologous recombination repair (HRR) genes and genomic instability (GI), employing formalin-fixed (FFPE) paraffin-embedded tumor samples without matched normal tissue. We therefore established a DNA-based hybrid capture NGS assay and an associated bioinformatic pipeline that fulfils our institution's specific needs. The assay´s target regions cover the full exonic territory of relevant cancer-related genes and HRR genes and more than 20,000 evenly distributed single nucleotide polymorphism (SNP) loci to allow for the detection of genome-wide allele specific copy number alterations (CNA).
View Article and Find Full Text PDFJoint ENGOT and GOG Foundation requirements for trials with industry partners.
Gynecol Oncol
August 2019
GOG-F and Gynecologic Oncology, Ohio State University Wexner Medical Center and JamesCare Gynecologic Oncology at Mill Run, Columbus, Ohio, USA.
Joint ENGOT and GOG Foundation requirements for trials with industry partners.
Int J Gynecol Cancer
September 2019
GOG-F and Gynecologic Oncology, Ohio State University Wexner Medical Center and JamesCare Gynecologic Oncology at Mill Run, Columbus, Ohio, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!